Anna C S Tan1, Suzanne Yzer2, Neal Atebara3, Brian P Marr4, Robert M Verdijk5, Virgil A S H Dalm6, K Bailey Freund7, Lawrence Yannuzzi7, Tom Missotten2. 1. Vitreous Retina Macula Consultants of New York, New York, New York; LuEsther T. Mertz Retinal Research Center, Manhattan, Eye, Ear and Throat Hospital, New York, New York; Singapore National Eye Center/Singapore Eye Research Institute, Singapore. Electronic address: annacstan@gmail.com. 2. The Rotterdam Eye Hospital, Rotterdam, Netherlands. 3. Retina Center of Hawaii, Honolulu, Hawaii. 4. Memorial Sloan Kettering Cancer Center, New York, New York. 5. Department of Pathology, Section Ophthalmic Pathology, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands. 6. Departments of Internal Medicine & Immunology, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands. 7. Vitreous Retina Macula Consultants of New York, New York, New York; LuEsther T. Mertz Retinal Research Center, Manhattan, Eye, Ear and Throat Hospital, New York, New York.
Abstract
PURPOSE: To report intraocular manifestations of Erdheim-Chester Disease (ECD) with multimodal imaging. DESIGN: A retrospective observational case series. METHODS: This was a multicenter case series of 3 patients with confirmed tissue diagnosis of ECD that showed intraocular manifestations and were imaged at baseline and follow-up visits. RESULTS: Intraocular manifestations are rarely observed in association with ECD. Intraocular manifestations of ECD seen on multimodal imaging include histiocytic choroidal infiltration causing choroidal lesions, complicated by recurrent serous retinal detachment (SRD). Short-term resolution of SRD was observed with ocular therapies including intravitreal injections of anti-vascular endothelial growth factor or verteporfin photodynamic therapy in combination with systemic chemotherapy therapies and oral corticosteroids; however, recurrences were common. Chorioretinal biopsy confirmed the diagnosis of ECD in 1 case, with the presence of histiocytic infiltration, fibrosis, and characteristic immunohistologic staining. In another case, with a novel ARAF positive mutation, treatment with sorafenib showed regression of the choroidal lesions and resolution of the SRD on multimodal imaging. These lesions were previously resistant to other forms of therapy. CONCLUSIONS: Rare intraocular manifestations of ECD confirmed on histopathology can be imaged with multimodal imaging. We report 3 cases, including 1 case diagnosed through histology from chorioretinal biopsy and another case associated with a novel ARAF mutation responsive to targeted therapy with sorafenib. The identification of novel somatic mutation associated with ECD enabled treatment with a new-targeted systemic agent. Multimodal imaging in these cases can also be used to monitor response to therapy.
PURPOSE: To report intraocular manifestations of Erdheim-Chester Disease (ECD) with multimodal imaging. DESIGN: A retrospective observational case series. METHODS: This was a multicenter case series of 3 patients with confirmed tissue diagnosis of ECD that showed intraocular manifestations and were imaged at baseline and follow-up visits. RESULTS: Intraocular manifestations are rarely observed in association with ECD. Intraocular manifestations of ECD seen on multimodal imaging include histiocytic choroidal infiltration causing choroidal lesions, complicated by recurrent serous retinal detachment (SRD). Short-term resolution of SRD was observed with ocular therapies including intravitreal injections of anti-vascular endothelial growth factor or verteporfin photodynamic therapy in combination with systemic chemotherapy therapies and oral corticosteroids; however, recurrences were common. Chorioretinal biopsy confirmed the diagnosis of ECD in 1 case, with the presence of histiocytic infiltration, fibrosis, and characteristic immunohistologic staining. In another case, with a novel ARAF positive mutation, treatment with sorafenib showed regression of the choroidal lesions and resolution of the SRD on multimodal imaging. These lesions were previously resistant to other forms of therapy. CONCLUSIONS: Rare intraocular manifestations of ECD confirmed on histopathology can be imaged with multimodal imaging. We report 3 cases, including 1 case diagnosed through histology from chorioretinal biopsy and another case associated with a novel ARAF mutation responsive to targeted therapy with sorafenib. The identification of novel somatic mutation associated with ECD enabled treatment with a new-targeted systemic agent. Multimodal imaging in these cases can also be used to monitor response to therapy.
Authors: Moozhan Nikpanah; Lauren Kim; S Mojdeh Mirmomen; Rolf Symons; Ioannis Papageorgiou; William A Gahl; Kevin O'Brien; Juvianee I Estrada-Veras; Ashkan A Malayeri Journal: Eur Radiol Date: 2018-03-19 Impact factor: 5.315
Authors: Ankush Bhatia; Vaios Hatzoglou; Gary Ulaner; Raajit Rampal; David M Hyman; Omar Abdel-Wahab; Benjamin H Durham; Ahmet Dogan; Neval Ozkaya; Mariko Yabe; Kseniya Petrova-Drus; Katherine S Panageas; Anne Reiner; Marc Rosenblum; Eli L Diamond Journal: Neuro Oncol Date: 2020-07-07 Impact factor: 12.300
Authors: Laura C Huang; Katie L Topping; Dita Gratzinger; Ryanne A Brown; Beth A Martin; Ruwan A Silva; Andrea L Kossler Journal: Am J Ophthalmol Case Rep Date: 2018-07-25
Authors: Victoria K Shanmugam; Marc Phillpotts; Timothy Brady; Monica Dalal; Shawn Haji-Momenian; Esma Akin; Kavita Nataranjan; Sean McNish; Donald S Karcher Journal: BMC Rheumatol Date: 2019-08-01